Literature DB >> 18855701

Alpha-synuclein misfolding and neurodegenerative diseases.

Vladimir N Uversky1.   

Abstract

Alpha-synuclein is an abundant presynaptic brain protein, misfolding, aggregation and fibrillation of which are implicated as critical factors in several neurodegenerative diseases. The list of the well-known synucleinopathies includes such devastating disorders as Parkinson's disease, Lewy body variant of Alzheimer's disease, diffuse Lewy body disease, dementia with Lewy bodies, multiple system atrophy, and neurodegeneration with brain iron accumulation type I. The precise functions of alpha-synuclein remain elusive, but there are evidence indicating its involvement in regulation vesicular release and/or turnover and synaptic function in the central nervous system. It might play a role in neuronal plasticity responses, bind fatty acids, regulate certain enzymes, transporters, and neurotransmitter vesicles, be involved in neuronal survival and even can act as a molecular chaperone. Structurally, alpha-synuclein is an illustrative member of the rapidly growing family of natively unfolded (or intrinsically disordered) proteins and considerable knowledge has been accumulated about its structural properties and conformational behavior. The molecular mechanisms underlying misfolding, aggregation and fibrillation of alpha-synuclein and the role of various environmental and genetic factors in stimulation and inhibition of these processes are relatively well understood. Here, the main structural features of alpha-synuclein, its functions, and involvement in various human diseases are summarized providing a foundation for better understanding of the biochemistry, biophysics and neuropathology of alpha-synuclein aggregation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855701     DOI: 10.2174/138920308785915218

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  68 in total

Review 1.  Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.

Authors:  Dawn Béraud; Kathleen A Maguire-Zeiss
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Supramolecular non-amyloid intermediates in the early stages of α-synuclein aggregation.

Authors:  Jonathan A Fauerbach; Dmytro A Yushchenko; Sarah H Shahmoradian; Wah Chiu; Thomas M Jovin; Elizabeth A Jares-Erijman
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

Review 3.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

4.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

5.  Reversible aggregation of PABPN1 pre-inclusion structures.

Authors:  Vered Raz; Tsion Abraham; Erik W van Zwet; Roeland W Dirks; Hans J Tanke; Silvère M van der Maarel
Journal:  Nucleus       Date:  2011 May-Jun       Impact factor: 4.197

6.  Cysteine cathepsins are essential in lysosomal degradation of α-synuclein.

Authors:  Ryan P McGlinchey; Jennifer C Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

7.  Amino acid analog toxicity in primary rat neuronal and astrocyte cultures: implications for protein misfolding and TDP-43 regulation.

Authors:  Kalavathi Dasuri; Philip J Ebenezer; Romina M Uranga; Elena Gavilán; Le Zhang; Sun O K Fernandez-Kim; Annadora J Bruce-Keller; Jeffrey N Keller
Journal:  J Neurosci Res       Date:  2011-05-23       Impact factor: 4.164

8.  Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions.

Authors:  Wenbo Zhou; Chunmei Long; Stephen H Reaney; Donato A Di Monte; Anthony L Fink; Vladimir N Uversky
Journal:  Biochim Biophys Acta       Date:  2009-12-21

9.  Protein disorder in the human diseasome: unfoldomics of human genetic diseases.

Authors:  Uros Midic; Christopher J Oldfield; A Keith Dunker; Zoran Obradovic; Vladimir N Uversky
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

10.  Unfoldomics of human diseases: linking protein intrinsic disorder with diseases.

Authors:  Vladimir N Uversky; Christopher J Oldfield; Uros Midic; Hongbo Xie; Bin Xue; Slobodan Vucetic; Lilia M Iakoucheva; Zoran Obradovic; A Keith Dunker
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.